A Phase 1 interventional study of [14C]-MRM-3379 in Healthy Volunteers, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Mirum Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1, open label study in healthy male participants to study the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379 drug following a single oral dose.
Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive a single dose of 5 mg \[14C\]-MRM-3379.
Drug: [14C]-MRM-3379
Oral capsule administered on Day 1 only.
Also known as: MRM-3379
Total radioactivity recovery of MRM-3379 in urine and feces
Evaluate the cumulative and total radioactivity in urine and feces following administration of a single oral dose of radiolabeled MRM-3379.
Time frame: Up to 11 days post dose
Maximum observed concentration (Cmax) of MRM-3379 and 2 metabolites in plasma
Time frame: Up to 11 days post dose
Time to maximum observed concentration (tmax) of MRM-3379 and 2 metabolites in plasma
Time frame: up to 11 days post dose
Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-tlast) of MRM-3379 and 2 metabolites in plasma
Time frame: up to 11 days post dose
Maximum observed concentration (Cmax) of total radioactivity in plasma and whole blood
Time frame: up to 11 days post dose
Time to maximum observed concentration (tmax) of total radioactivity in plasma and whole blood
Time frame: up to 11 days post dose
Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-tlast) of total radioactivity in plasma and whole blood
Time frame: Up to 11 days post dose
Amount of MRM-3379 and 2 metabolites excreted in the urine (Ae) over sampling period
Time frame: Up to 11 days post dose
Fraction of MRM-3379 and 2 metabolites excreted in the urine (Fe) as Ae/dose
Time frame: Up to 11 days post dose
Renal clearance of MRM-3379 as Ae/AUC
Time frame: Up to 11 days post dose
Assessment of metabolites in plasma and excreta by liquid chromatography-radiochemical-detection and subsequent mass spectrometry
Evaluate the quantitative metabolic profile of MRM-3379 in plasma, urine, and feces via radiochromatographic profiles and identify associated metabolites following administration of a single oral dose of radiolabeled MRM-3379.
Time frame: Up to 11 days post dose
Number of subjects with treatment-related adverse events
Time frame: Up to 11 days post dose
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2026 to primary completion in Jul 2026, 1 month.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.